Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.62 |
| ▸ | PTGDR | Q13258 | 7/20 | 0.62 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148095 | 1.00 | PTGDR2 (0.62) | PTGDR2PTGDRPTGER2SLC6A9KDM4E | |
| SCHEMBL4882270 | 0.77 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2WDR5 | |
| SCHEMBL4882946 | 0.77 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2WDR5 | |
| SCHEMBL13262573 | 0.74 | PTGDR2 (0.59) | PTGDR2PTGDRPTGER2SLC6A9KDM4E | |
| SCHEMBL4885235 | 0.73 | PTGDR2 (0.61) | PTGDR2PTGDRPTGER2SLC6A9MEN1 | |
| SCHEMBL491171 | 0.73 | CHEK1 (0.49) | MEN1KMT2A | |
| SCHEMBL21060488 | 0.72 | PTGDR2 (0.86) | PTGDR2PTGDRPTGER2WDR5 | |
| SCHEMBL22805075 | 0.71 | PTGDR2 (0.53) | PTGDR2PTGDRPTGER2KDM4EMEN1 | |
| SCHEMBL22804878 | 0.71 | PTGDR2 (0.53) | PTGDR2PTGDRPTGER2KDM4EMEN1 | |
| SCHEMBL22804880 | 0.71 | PTGDR2 (0.53) | PTGDR2PTGDRPTGER2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106091-B2 | Inhibitors of IKK-beta serine-threonine protein kinase | CHROMA THERAPEUTICS LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| EP-2086956-B1 | INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD (GB) | 2011-09-14 | — | — | EP | disclosed |
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2010-03-18 | — | — | US | disclosed |
| EP-2086956-A1 | INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE | Chroma Therapeutics Limited (GB) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008053185-A1 | INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | IKBKB, IKBKE, CHUK | PTGDR2 2832/4885PTGDR 2467/4885PTGER2 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.